Moderna (MRNA 2.32%) says it is developing vaccines against the coronavirus variants "out of an abundance of caution." But as Fool.com contributors Brian Orelli and Keith Speights discuss in this video from Motley Fool Live, recorded on April 12, the need for vaccines against the variants appears inevitable.

10 stocks we like better than Moderna
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of February 24, 2021

 

Brian Orelli: In Moderna's press release, it says, and I'm quoting here, "Out of an abundance of caution, Moderna is also pursuing a clinical development strategy against the emerging variants," which we already knew that. But I just found it curious. First off, with the coronavirus variants, have we reached a point where we're doing this just in case it's needed? Then do you want to give us a timeline on the potential booster shots in advance?

Keith Speights: Obviously Moderna doesn't think that we're beyond that point of moving forward out of an abundance of caution. It is kind of funny the wording they use in some of their press releases, but aside from that wording, putting it aside, I think the drug makers are legitimately continuing to explore the best approach to providing protection against new variants.

As for the timelines for potential booster shots, for Moderna, the National Institute of Health, NIH, is testing a booster dose of a modified version of Moderna's vaccine. They expect to be fully enrolled in this study by the end of April. So just a few weeks from now. Moderna has publicly stated that it expects to have a booster shot available by the end of 2021. Moderna has gone on the record projecting when they think they'll have this booster shot available.

It's a little different story with Pfizer (PFE -1.07%). Pfizer and BioNTech (BNTX -0.78%) are testing a third dose of their existing vaccine. In late February, the two companies said that they were also talking with regulatory authorities about the potential for advancing a modified version of their vaccine that specifically targets these variants in the clinical testing. But I haven't seen an update from Pfizer or BioNTech on this testing effort, haven't seen any specific timelines about the booster shots from either company.

I think though that just based on what we do know, I think that Pfizer could be a little ahead of Moderna with the testing of a third dose of its existing vaccine and probably a little behind with testing of a modified vaccine that's specific to these variants. So we'll just see how this plays out.